[Featured Stock] SK Bioscience Gains 5% Ahead of COVID-19 Vaccine Clinical Trial Announcement

On the 18th, at the Korea Exchange in Yeongdeungpo-gu, Seoul, Ahn Jae-yong, CEO of SK Bioscience, a vaccine development and manufacturing company, received the listing contract and listing commemorative plaque from Sohn Byung-doo, Chairman of the Korea Exchange, at the KOSPI new listing ceremony of SK Bioscience. Photo by Hyunmin Kim kimhyun81@

[Asia Economy Reporter Ji Yeon-jin] On the 27th, SK Bioscience is showing strong performance ahead of the announcement of COVID-19 vaccine clinical trial results amid the resurgence of the virus.

As of 10:48 AM on the same day, SK Bioscience was trading at 288,500 KRW on the KOSPI market, up 5.10% (14,000 KRW) compared to the previous trading day.

The company is conducting Korea's first Phase 3 clinical trial for a COVID-19 vaccine and plans to disclose interim results of Phase 1 and 2 trials after October. SK Bioscience, in collaboration with the International Vaccine Institute (IVI), plans to start Phase 3 clinical trials in overseas regions such as Eastern Europe and Southeast Asia, through a non-profit international organization, as early as September.

Additionally, SK Bioscience is expected to complete the Phase 3 clinical trial of GBP510 in the first half of next year and sign a contract to supply large quantities to COVAX.

This content was produced with the assistance of AI translation services.